Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly will submit orforglipron to be part of FDA’s new national priority voucher program, according to a new report. 1 ...

The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company ...

Recursion, Roche and Genentech unveiled the latest product of their nearly four-year artificial intelligence drug discovery collaboration. GSK ’s Blenrep was approved by the FDA for treatment of ...

Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion ...

New Scripps Research trial will explore the effects of Lilly’s GLP-1 drug on reducing the symptoms of the debilitating ...

As of Wednesday, when the stock rose 3%, Nvidia was larger than Qualcomm, AMD, Arm Holdings, ASML, Broadcom, Intel, Lam ...

For Indian pharmaceutical companies that already supply nearly half of all generic medicines sold in the US, the decision ...

According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have ...

The New York-based biotech is at the centre of a bidding war between ... Metsera’s lead candidate, MET-097i, is a ...

One writer felt she'd finally reached her bodily happy ever after via GLP-1 jabs. But with soaring prices and scientific unknowns on the horizon...now what?

confusion and introspection around a new generation of weight-loss drugs that have entered Indian markets in 2025. While ...